Compare
Pit 2–4 stocks against each other: U-Score, pillars, fundamentals, and normalized price history. Same universe, same methodology, one view.
| Metric | BALPHARMA Bal Pharma Limited Pharma · Small | BALAXI BALAXI PHARMACEUTICALS LIMITED Pharma · Small | BROOKS Brooks Laboratories Limited Pharma · Small | ACCPL Accretion Pharmaceuticals Ltd. Pharma · SME |
|---|---|---|---|---|
| Final Score | 19 | 10 | 69 | 59 |
| Verdict | OVERVALUED | OVERVALUED | UNDERVALUED | FAIR VALUE |
| Style | Distress Watch | OVERVALUED | Deep Value | Growth at Value |
| Piotroski | 6/9 | 3/9 | 8/9 | 6/9 |
| Valuation | 7/30 | 4/30 | 27/30 | 18/30 |
| Growth | 8/25 | 1/25 | 18/25 | 19/25 |
| Quality | 0/20 | 0/20 | 13/20 | 16/20 |
| Balance Sheet | 0/15 | 10/15 | 11/15 | 12/15 |
| Cash Flow | 9/10 | 1/10 | 3/10 | 0/10 |
| Price | ₹87.79 | ₹24.22 | ₹68.23 | ₹133.5 |
| P/E | 21.60 | 95.20 | 7.99 | 15.40 |
| P/B | 1.65 | 0.54 | 1.60 | 2.72 |
| ROE | 7.87% | 0.59% | 22.30% | 27.60% |
| ROCE | 9.69% | 3.11% | 21.50% | 28.90% |
| Debt / Equity | 1.95 | 0.23 | 0.07 | 0.23 |
| FCF Yield | 6.67% | — | 3.06% | — |
| Dividend Y | 1.41% | — | — | — |
| Altman Z | 1.71 | 3.06 | 6.44 | 6.94 |
| Promoter % | 50.87% | 65.99% | 52.62% | 73.52% |
| Mkt Cap (₹Cr) | 135.00 | 135.00 | 196.00 | 149.00 |
| Graham # | ₹67.63 | ₹16.24 | ₹88.35 | ₹98.14 |
| Fair PE | 16.1 | 0.9 | 42.0 | 42.0 |
| MoS % | -38.7% | -10731.4% | +80.5% | +63.5% |
Normalized price (3-year, indexed to 100)
Higher line = better relative performance from startBALPHARMA71
BALAXI28
BROOKS49
ACCPL179